Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
S.T. Kim(Samsung Medical Center), Eirini Pectasides, Richard B. Lanman(Guardant (United States)), J.H. Lee(Samsung Medical Center), Ho Yeong Lim(Samsung Medical Center), Naomy Kim(Samsung Medical Center), Joon Oh Park(Samsung Medical Center), Jae-Moon Bae(Samsung Medical Center), Kimberly C. Banks(Guardant (United States)), AmirAli Talasaz(Stanford University), Won Ki Kang(Samsung Medical Center), Ji Yeong An(Samsung Medical Center), Adam J. Bass(Broad Institute), Y.S. Park(Samsung Medical Center), Hyunwoo Lee, Sun Young Kim(Sungkyunkwan University), Kihyun Kım(State University of New York), M.G. Choi(Samsung Medical Center), Tae Sung Sohn(Samsung Medical Center), Woong‐Yang Park(Samsung (South Korea)), S.H. Park(Samsung Medical Center)
Cited by 105
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
|Nature Genetics|2011|1.1k